Infections caused by protozoans remain a public health issue, especially in tropical countries. Serious adverse events, lack of efficacy at the different stages of the infection and routes of administration that have a negative impact on treatment adherence are some of the problems with currently available therapy against these diseases. Here we describe an epigenetic target, sirtuin 2 and its related proteins, that is promising given the results in phenotypic assays and models against Sir2 of , , , , and parasites. The results we present highlight how this target can be extensively explored and how its inhibitors might be employed in the clinic.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4155/fmc-2021-0091 | DOI Listing |
Front Parasitol
March 2024
Disease Control Department, Moredun Research Institute, Edinburgh, United Kingdom.
Introduction: We previously demonstrated efficacy of an 8-antigen recombinant subunit vaccine against a single species homologous challenge in lambs and in lambing ewes in pen trials. We subsequently demonstrated efficacy of a simplified, 2-antigen, version of this vaccine in lambs in pen trials. Here, we test both vaccines in lambing ewes in a field setting.
View Article and Find Full Text PDFFront Parasitol
May 2024
Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands.
Detection of spp. DNA in gynaecological samples by quantitative real-time polymerase chain reaction (qPCR) is considered to be the reference diagnostic test for female genital schistosomiasis (FGS). However, qPCR needs expensive laboratory procedures and highly trained technicians.
View Article and Find Full Text PDFFront Parasitol
April 2024
INRS- Centre Armand-Frappier Santé Biotechnologie, Université du Québec, Laval, QC, Canada.
Extracellular vesicles released by the protozoan parasite display immunomodulatory properties towards mammalian immune cells. In this study, we have evaluated the potential of extracellular vesicles derived from the non-pathogenic protozoan towards the development of a vaccine adjuvant. As a proof of concept, we expressed in a codon-optimized SARS-CoV-2 Spike protein fused to the secreted acid phosphatase signal peptide in the N-terminal and to a 6×-His stretch in the C-terminal.
View Article and Find Full Text PDFFront Parasitol
September 2024
Institute for Medical Microbiology, Immunology, and Parasitology (IMMIP), University Hospital Bonn (UKB), Bonn, Germany.
Introduction: Schistosomiasis, a tropical parasitic disease, affects 779 million people globally, with 85% of cases in Africa. The interplay between schistosomiasis and other sexually transmitted infections (STIs) can exacerbate health burdens, but most attention has focused on interactions with HIV, neglecting coinfections with other STIs. This systematic review and meta-analysis aims to understand the role infections play in STIs within schistosomiasis-endemic populations.
View Article and Find Full Text PDFFront Parasitol
December 2023
Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Reticulocyte Binding Protein Homologue (RH5), a leading malaria vaccine candidate, is essential for erythrocyte invasion by the parasite, interacting with the human host receptor, basigin. RH5 has a small number of polymorphisms relative to other blood-stage antigens, and studies have shown that vaccine-induced antibodies raised against RH5 are strain-transcending, however most studies investigating RH5 diversity have been done in Africa. Understanding the genetic diversity and evolution of malaria antigens in other regions is important for their validation as vaccine candidates.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!